Ambu A/S Unsponsored ADR (OTCMKTS:AMBBY – Get Free Report) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 390 shares, a growth of 333.3% from the September 30th total of 90 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 19 shares, the short-interest ratio is presently 20.5 days.
Analyst Upgrades and Downgrades
Separately, UBS Group downgraded shares of Ambu A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 15th. One investment analyst has rated the stock with a Hold rating. Based on data from MarketBeat, Ambu A/S has a consensus rating of “Hold”.
Check Out Our Latest Research Report on AMBBY
Ambu A/S Stock Performance
Shares of AMBBY opened at $11.64 on Friday. The stock has a 50-day simple moving average of $11.00 and a 200-day simple moving average of $11.03. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.69 and a current ratio of 2.77. The stock has a market capitalization of $2.74 billion, a PE ratio of 38.80 and a beta of 0.92. Ambu A/S has a 1 year low of $8.54 and a 1 year high of $16.31.
Ambu A/S (OTCMKTS:AMBBY – Get Free Report) last announced its quarterly earnings data on Tuesday, August 25th. The company reported $0.09 EPS for the quarter. Ambu A/S had a return on equity of 8.49% and a net margin of 8.18%. The business had revenue of $255.12 million during the quarter.
About Ambu A/S
Ambu A/S is a Danish medical technology company that develops, manufactures and markets single-use devices for hospitals and other healthcare providers. Its products are designed to support clinical procedures while reducing the need for cleaning, disinfection and reprocessing associated with reusable equipment.
The company’s portfolio includes single-use endoscopy systems, such as the aScope range of flexible endoscopes and related visualization equipment, as well as products for anesthesia, airway management, ventilation, resuscitation and patient monitoring.
See Also
- Five stocks we like better than Ambu A/S
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Ambu A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambu A/S and related companies with MarketBeat.com's FREE daily email newsletter.
